Citadel Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $354K | Sell |
15,900
-10,100
| -39% | -$241K | ﹤0.01% | 10093 |
|
|
2025
Q4 | $694K | Sell |
26,000
-67,500
| -72% | -$1.61M | ﹤0.01% | 8228 |
|
|
2025
Q3 | $2M | Buy |
93,500
+28,400
| +44% | +$672K | ﹤0.01% | 6072 |
|
|
2025
Q2 | $1.4M | Buy |
65,100
+4,800
| +8% | +$89.2K | ﹤0.01% | 6394 |
|
|
2025
Q1 | $1M | Sell |
60,300
-32,400
| -35% | -$589K | ﹤0.01% | 6957 |
|
|
2024
Q4 | $1.7M | Buy |
92,700
+62,100
| +203% | +$1M | ﹤0.01% | 5963 |
|
|
2024
Q3 | $471K | Sell |
30,600
-35,000
| -53% | -$584K | ﹤0.01% | 8390 |
|
|
2024
Q2 | $1.07M | Sell |
65,600
-77,600
| -54% | -$1.25M | ﹤0.01% | 6455 |
|
|
2024
Q1 | $2.65M | Buy |
143,200
+29,500
| +26% | +$731K | ﹤0.01% | 4994 |
|
|
2023
Q4 | $3.56M | Sell |
113,700
-90,300
| -44% | -$2.16M | ﹤0.01% | 4344 |
|
|
2023
Q3 | $4.25M | Buy |
204,000
+187,100
| +1,107% | +$5.08M | ﹤0.01% | 3922 |
|
|
2023
Q2 | $405K | Sell |
16,900
-17,700
| -51% | -$393K | ﹤0.01% | 8391 |
|
|
2023
Q1 | $651K | Sell |
34,600
-19,800
| -36% | -$377K | ﹤0.01% | 7746 |
|
|
2022
Q4 | $866K | Sell |
54,400
-15,600
| -22% | -$244K | ﹤0.01% | 7080 |
|
|
2022
Q3 | $1.15M | Sell |
70,000
-242,400
| -78% | -$3.93M | ﹤0.01% | 6692 |
|
|
2022
Q2 | $4.4M | Buy |
312,400
+243,100
| +351% | +$4.54M | ﹤0.01% | 4051 |
|
|
2022
Q1 | $1.68M | Sell |
69,300
-102,400
| -60% | -$2.48M | ﹤0.01% | 6485 |
|
|
2021
Q4 | $4.01M | Buy |
171,700
+8,100
| +5% | +$163K | ﹤0.01% | 4742 |
|
|
2021
Q3 | $2.72M | Sell |
163,600
-49,800
| -23% | -$960K | ﹤0.01% | 5591 |
|
|
2021
Q2 | $5.21M | Sell |
213,400
-176,300
| -45% | -$3.98M | ﹤0.01% | 4337 |
|
|
2021
Q1 | $10.1M | Buy |
389,700
+276,700
| +245% | +$12.2M | ﹤0.01% | 2957 |
|
|
2020
Q4 | $6.04M | Sell |
113,000
-23,900
| -17% | -$1.19M | ﹤0.01% | 3366 |
|
|
2020
Q3 | $5.65M | Buy |
136,900
+28,700
| +27% | +$1.24M | ﹤0.01% | 2986 |
|
|
2020
Q2 | $5.24M | Buy |
108,200
+17,600
| +19% | +$845K | ﹤0.01% | 3019 |
|
|
2020
Q1 | $3.83M | Sell |
90,600
-326,600
| -78% | -$13.5M | ﹤0.01% | 3096 |
|
|
2019
Q4 | $17.8M | Buy |
417,200
+191,300
| +85% | +$8.32M | 0.01% | 1591 |
|
|
2019
Q3 | $8.13M | Buy |
225,900
+112,800
| +100% | +$3.42M | ﹤0.01% | 2465 |
|
|
2019
Q2 | $3.02M | Buy |
113,100
+51,900
| +85% | +$1.33M | ﹤0.01% | 3841 |
|
|
2019
Q1 | $1.64M | Sell |
61,200
-42,700
| -41% | -$997K | ﹤0.01% | 4777 |
|
|
2018
Q4 | $1.68M | Sell |
103,900
-58,900
| -36% | -$1.14M | ﹤0.01% | 4424 |
|
|
2018
Q3 | $3.38M | Buy |
162,800
+58,100
| +55% | +$914K | ﹤0.01% | 3546 |
|
|
2018
Q2 | $1.6M | Buy |
104,700
+29,400
| +39% | +$524K | ﹤0.01% | 4443 |
|
|
2018
Q1 | $1.69M | Buy |
75,300
+15,300
| +26% | +$424K | ﹤0.01% | 3993 |
|
|
2017
Q4 | $1.81M | Buy |
60,000
+20,500
| +52% | +$656K | ﹤0.01% | 3779 |
|
|
2017
Q3 | $1.49M | Sell |
39,500
-5,600
| -12% | -$182K | ﹤0.01% | 3782 |
|
|
2017
Q2 | $1.26M | Sell |
45,100
-20,500
| -31% | -$611K | ﹤0.01% | 3772 |
|
|
2017
Q1 | $2.25M | Sell |
65,600
-63,300
| -49% | -$2.23M | ﹤0.01% | 2941 |
|
|
2016
Q4 | $3.72M | Buy |
128,900
+43,600
| +51% | +$1.15M | ﹤0.01% | 2289 |
|
|
2016
Q3 | $2.71M | Sell |
85,300
-32,000
| -27% | -$1.08M | ﹤0.01% | 2618 |
|
|
2016
Q2 | $3.81M | Sell |
117,300
-71,900
| -38% | -$2.41M | ﹤0.01% | 2071 |
|
|
2016
Q1 | $5.29M | Buy |
189,200
+112,500
| +147% | +$2.45M | 0.01% | 1710 |
|
|
2015
Q4 | $2.73M | Sell |
76,700
-13,100
| -15% | -$462K | ﹤0.01% | 2429 |
|
|
2015
Q3 | $2.97M | Buy |
89,800
+20,900
| +30% | +$870K | ﹤0.01% | 2481 |
|
|
2015
Q2 | $2.89M | Sell |
68,900
-47,400
| -41% | -$1.83M | ﹤0.01% | 2631 |
|
|
2015
Q1 | $3.79M | Buy |
116,300
+63,200
| +119% | +$2.17M | ﹤0.01% | 2329 |
|
|
2014
Q4 | $1.69M | Sell |
53,100
-18,000
| -25% | -$510K | ﹤0.01% | 3118 |
|
|
2014
Q3 | $1.76M | Buy |
71,100
+6,200
| +10% | +$145K | ﹤0.01% | 2994 |
|
|
2014
Q2 | $1.47M | Sell |
64,900
-13,300
| -17% | -$278K | ﹤0.01% | 3046 |
|
|
2014
Q1 | $1.9M | Buy |
78,200
+5,600
| +8% | +$142K | ﹤0.01% | 2716 |
|
|
2013
Q4 | $1.81M | Sell |
72,600
-26,900
| -27% | -$635K | ﹤0.01% | 2633 |
|
|
2013
Q3 | $2.73M | Sell |
99,500
-19,800
| -17% | -$414K | ﹤0.01% | 2110 |
|
|
2013
Q2 | $2.17M | Buy |
+119,300
| New | +$1.64M | ﹤0.01% | 2416 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Citadel Advisors's ACAD Position: Q1 2026 in Review
Citadel Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 54% in Q1 2026, selling an estimated $17.8M and leaving 622,760 shares worth $13.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2784.
Citadel Advisors first reported a position in ACAD in Q2 2013 and has held it in 51 quarters since. The position peaked at $187M in Q2 2020. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Citadel Advisors held 622,760 shares of Acadia Pharmaceuticals worth $13.9M as of Q1 2026.
- Citadel Advisors sold 744,699 Acadia Pharmaceuticals shares in Q1 2026, an estimated $17.8M.
- Acadia Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2784 holding.
- Citadel Advisors first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Citadel Advisors's Acadia Pharmaceuticals position peaked at $187M in Q2 2020.
- 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.